Boardroom Alpha
Boardroom Alpha
ISPC · Additional Proxy Materials (DEFA14A) · Filed March 3, 2026

Ispecimen Inc — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
March 3, 2026
Ticker
ISPC
Accession
0001213900-26-023026
Boardroom Alpha · Filing insights

iSpecimen Inc. confirms Siyun Yang resignation and removal from slate; remaining nominees will be elected at the March 13, 2026 meeting.

About Ispecimen Inc
Market cap
$4M
1Y TSR
−90.4%
3Y TSR
−84.5%
Board grade
D
Sector
Healthcare
CEO
Katharyn Field
Last annual meeting: Dec 31, 2025 · View full Ispecimen Inc profile →

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

SCHEDULE 14A INFORMATION

 

 

 

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

 

Filed by the Registrant  
Filed by a Party other than the Registrant  

 

Check the appropriate box:

 

Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to § 240.14a-12

 

iSpecimen Inc.
(Name of Registrant as Specified in its Charter)

 

N/A
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

PAYMENT OF FILING FEE (Check the appropriate box):

 

No fee required.
Fee paid previously with preliminary materials.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

 

 

 

 

 

 

EXPLANATORY NOTE

 

This amendment (this “Amendment”), dated March 3, 2026, amends and supplements the definitive proxy statement filed by iSpecimen Inc., a Delaware corporation (the “Company”), with the Securities and Exchange Commission (the “SEC”) on November 21, 2025 (the “Proxy Statement”), in connection with the Company’s 2025 Annual Meeting of Stockholders (the “Annual Meeting”).

 

As previously disclosed, the Annual Meeting was convened on December 31, 2025 and adjourned due to the absence of a quorum. The Annual Meeting was subsequently reconvened on January 23, 2026 and February 13, 2026, and at each reconvened meeting a quorum was not present and the meeting was adjourned. The Company intends to reconvene the Annual Meeting on March 13, 2026, at 9:00 a.m. Eastern Time. The record date for the Annual Meeting remains November 3, 2025.

 

On February 17, 2026, Ms. Siyun Yang resigned as a member of the Company’s Board of Directors, effective immediately, as disclosed in the Company’s Current Report on Form 8-K filed with the SEC on February 17, 2026.

 

This Amendment is being filed to reflect Ms. Yang’s resignation and to clarify that she is no longer a nominee for election at the Annual Meeting.

 

Amendment to Proposal No. 1 - Election of Directors

 

The disclosure in the Proxy Statement relating to Proposal No. 1 - Election of Directors is hereby amended as follows:

 

Ms. Siyun Yang is no longer serving as a member of the Company’s Board of Directors and is no longer a nominee for election at the Annual Meeting. Accordingly, all references in the Proxy Statement to Ms. Yang as a nominee for election are deleted.

 

As a result, Proposal No. 1 will now provide for the election only of the remaining nominees named in the Proxy Statement. The Board of Directors currently intends that the remaining nominees will continue to stand for election as described in the Proxy Statement.

 

If you have already returned a proxy card or provided voting instructions and do not wish to change your vote, you do not need to take any further action. Any votes previously submitted with respect to Proposal No. 1 will be voted only with respect to the remaining nominees for election.

 

Except as specifically amended or supplemented by the information contained herein, this Amendment does not revise or update any other information set forth in the Proxy Statement. This Amendment should be read in conjunction with the Proxy Statement, and the Proxy Statement should be read in its entirety.

 

 

 

 

 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Ispecimen Inc (ISPC)

Reference

Frequently asked questions

When did Ispecimen Inc file this DEFA14A?
Ispecimen Inc (ISPC) filed this Additional Proxy Materials (DEFA14A) with the SEC on March 3, 2026. The accession number assigned by EDGAR is 0001213900-26-023026.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
iSpecimen Inc. confirms Siyun Yang resignation and removal from slate; remaining nominees will be elected at the March 13, 2026 meeting. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Ispecimen Inc's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Ispecimen Inc has filed under CIK 1558569, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer

Ispecimen Inc (ISPC) DEFA14A filed Mar 3, 2026